Project description:Hepatocellular carcinoma (HCC) is a rapidly increasing and highly lethal cancer worldwide, with many patients diagnosed at advanced stages and early-stage patients often experiencing high recurrence rates. The combination of atezolizumab plus bevacizumab emerged as a groundbreaking immunotherapy, establishing a new standard of care for advanced HCC. There's an urgent need for reliable biomarkers to predict patient responses and personalize treatment. We collected tumor samples from advanced HCC patients wirth atezolizumab plus bevacizumab therapy and performed comprehensive analyses of the tumor microenvironment using bulk RNA sequencing to identify key features influencing the effectiveness of atezolizumab plus bevacizumab.

2025-10-02 | GSE285963 | GEO

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma.

Project description: Not available

| S-EPMC11794155 | biostudies-literature

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.

Project description: Not available

| S-EPMC10386929 | biostudies-literature

T-Cell Dynamics Predicts Prognosis of Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Project description: Not available

| S-EPMC11507274 | biostudies-literature

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab.

Project description: Not available